PROCEPT BioRobotics Corp
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
PRCT$22.37+8.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Financial Statements: Consolidated Balance Sheets F-
(in thousands, except per share data)
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $257,222 | $221,859 |
| Restricted cash, current | — | 777 |
| Accounts receivable, net | 48,376 | 15,272 |
| Inventory | 39,756 | 28,543 |
| Prepaid expenses and other current assets | 5,213 | 6,175 |
| Total current assets | 350,567 | 272,626 |
| Restricted cash, non-current | 3,038 | 3,038 |
| Property and equipment, net | 28,748 | 8,656 |
| Operating lease right-of-use assets, net | 20,241 | 23,481 |
| Intangible assets, net | 1,204 | 1,477 |
| Other assets | 919 | 51 |
| Total assets | $404,717 | $309,329 |
| Liabilities and Stockholders' Equity (Deficit) | ||
| Current liabilities: | ||
| Accounts payable | $13,499 | $9,391 |
| Accrued compensation | 16,885 | 13,447 |
| Deferred revenue | 5,656 | 2,855 |
| Operating leases, current | 1,683 | 2,129 |
| Loan facility derivative liability, current | 1,886 | — |
| Other current liabilities | 6,318 | 7,468 |
| Total current liabilities | 45,927 | 35,290 |
| Long-term debt | 51,339 | 51,213 |
| Operating leases, non-current | 26,182 | 23,975 |
| Loan facility derivative liability, non-current | — | 1,779 |
| Other non-current liabilities | 517 | — |
| Total liabilities | 123,965 | 112,257 |
| Commitments and contingencies (Note 11) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.00001 par value; | ||
| Authorized shares: 10,000 at December 31, 2023 and 2022, respectively | ||
| Issued and outstanding shares: none at December 31, 2023 and 2022 | — | — |
| Common stock, $0.00001 par value; | ||
| Authorized shares: 300,000 at December 31, 2023 and 2022, respectively | ||
| Issued and outstanding shares: 50,771 and 44,828 at December 31, 2023 and 2022, respectively | — | — |
| Additional paid-in capital | 735,240 | 545,753 |
| Accumulated other comprehensive gain (loss) | 84 | (6) |
| Accumulated deficit | (454,572) | (348,675) |
| Total stockholders’ equity | 280,752 | 197,072 |
| Total liabilities and stockholders’ equity | $404,717 | $309,329 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.